Wolfgang Miesbach;Robert Klamroth/LinkedIn
Feb 13, 2026, 11:00
Wolfgang Miesbach: 5 Year Liver Safety Outcomes After Gene Therapy for Severe Haemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
“Impressed by the detailed safety focus in EAHAD2026 session on valoctocogene roxaparvovec gene therapy for severe haemophilia A.
Robert Klamroth presented a 5‑year characterisation of ALT elevations in the phase 3 GENEr8‑1 trial, offering very concrete insights into liver safety after gene transfer:
- ALT elevations were the most common adverse event, occurring in most participants in year 1 after infusion, then falling sharply and stabilising in years 2–5.
- The vast majority of ALT elevations were mild (≤3× ULN), asymptomatic and transient, with events >5× ULN being rare and no clear signal for progressive liver injury.
- Glucocorticoids were used predominantly in years 1–2 and only in those with ALT >ULN, allowing targeted management of liver enzyme rises while avoiding prolonged steroid exposure for most patients.
- Over the full 5‑year period, the safety profile remained consistent with earlier read‑outs, supporting durable bleed protection and quality‑of‑life gains with valoctocogene roxaparvovec as a one‑time treatment option.
These data reinforce that careful monitoring, clear steroid algorithms and long‑term follow‑up are essential to delivering AAV gene therapy.”

Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance